Cooper Companies

The Cooper Cos, Inc. operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues. The Cooper Surgical segment focuses on the provision of advancement for the health of women, babies, and families through women's health and fertility products and services. The company was founded in 1958 and is headquartered in San Ramon, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Cooper Companies excels in Q1, eyes growth through strategic initiatives

Cooper Companies delivered exceptional Q1 results, surpassing revenue and earnings expectations. With a focus on innovation, operational efficiency, and strategic acquisitions, the company is well-positioned for continued growth despite economic uncertainties and supply chain challenges.

Cooper Companies reports record Q2 revenues amidst industry challenges

Cooper Companies delivered a strong Q2 performance with record revenues and solid earnings per share, driven by CooperVision and CooperSurgical.
While facing industry-wide supply chain challenges, Cooper's strategic strengths in product portfolios and geographic diversification position it well for future growth.
Opportunities lie in leveraging successful product lines, addressing operational challenges, and expanding into international markets for sustained growth.
Overall, Cooper remains optimistic about its future growth prospects in the contact lens and fertility markets, despite facing some challenges.

Cooper Companies reports record revenues and optimistic outlook for growth

Cooper Companies delivered strong financial performance, exceeding revenue expectations and showcasing growth in key segments. The company is strategically positioned for sustained growth, with a focus on leveraging market opportunities and optimizing infrastructure investments. Challenges in managing growth and SKU ranges are being addressed to drive future profitability.

Cooper Companies reports record revenues and projects strong growth ahead

Cooper Companies had a stellar year, marked by record revenues and robust growth in key segments. Despite challenges in capacity and cash flow, the company is poised for continued success with confidence in overcoming obstacles. Opportunities in Myopia management, price trends, and share gains position Cooper Companies for a promising future.

Cooper Companies reports record Q1 revenues, eyes global growth opportunities

Cooper Companies delivered a strong Q1 performance with record revenues and raised full-year guidance. The company's focus on key growth areas like myopia management and daily contact lenses bodes well for future success. Addressing challenges in capacity constraints and market fluctuations will be crucial for sustained growth.

Cooper Companies (COO) reports record revenues and growth opportunities

Cooper Companies (COO) reports strong Q2 earnings with record revenues and increased guidance for fiscal 2024. Challenges include system upgrade impact and competitive uncertainties, but opportunities lie in market growth and strategic investments for future growth.

Cooper Companies (COO) excels in Q3 with record revenues and growth

Cooper Companies (COO) showcased robust financial performance in Q3 2024, driven by record revenues and earnings growth across its key segments.
While facing challenges in certain product lines, strategic investments and market-leading positions position the company well for future growth and profitability.
With a focus on innovation and operational excellence, Cooper Companies is poised to capitalize on opportunities for sustained success and market expansion.

Cooper Companies reports record revenues in Q4 2024 earnings call

Cooper Companies delivered a strong performance in Q4 2024, with record revenues and notable growth in both CooperVision and CooperSurgical segments. While facing challenges with Paragard sales, the company is focused on capitalizing on opportunities in expanding product lines and myopia management for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.

Cooper Companies (COO) Q1 Earnings & Revenues Beat Estimates

The Cooper Companies (COO) delivered earnings and revenue surprises of 5.19% and 6.84%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

The Cooper Companies (COO) Q1 Earnings and Revenues Beat Estimates

SAN RAMON, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced financial results for its first quarter of fiscal year 2022, which ended January 31, 2022.

CooperCompanies Announces First Quarter 2022 Results

The Cooper Companies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why The Cooper Companies (COO) Might Surprise This Earnings Season

The Cooper Companies (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Cooper Companies (COO) Expected to Beat Earnings Estimates: Should You Buy?

SAN RAMON, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will present at Oppenheimer's 32nd Annual Healthcare Conference on Wednesday, March 16, 2022. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a virtual session scheduled to begin at 3:20 PM ET.

CooperCompanies to Present at Oppenheimer's 32nd Annual Healthcare Conference

Medical device company CooperCompanies Inc (NYSE: COO) has signed a binding agreement to buy Cook Medical's Reproductive Health business in an $875 million deal. Indiana-based Cook Medical is a privately held firm primarily involved in the manufacturing of medical devices.

CooperCompanies Scoops Up Cook Medical's Reproductive Health Business For $875M

BLOOMINGTON, Ind.--(BUSINESS WIRE)-- #cookmedical--Cook Medical today announced it signed a letter of intent with CooperCompanies to sell the entirety of Cook's Reproductive Health business within the MedSurg division. CooperCompanies (NYSE:COO), a publicly held healthcare company, is focused on women's health and fertility solutions, providing innovative products and services for every step in the ART journey. Under the proposed transaction, CooperCompanies will pay $875 million comprised of $675 million at

Cook Medical Reproductive Health Business to be Acquired by CooperCompanies

Acquisition will enhance CooperSurgical's international fertility footprint and medical device portfolio

CooperCompanies to Acquire Cook® Medical's Reproductive Health Business

Sometimes, you're willing to forgo potentially big gains for a stock that lets you sleep at night, because the share price stays steady. Cooper Companies Inc. ( COO , Financial) delivers that steadiness—and has beaten the S&P 500 ETF Trust ( SPY , Financial) (a proxy for the S&P 500) by an average of 3.39% per year over the past 10 years:

Cooper Companies: No Drama, Steady Growth

SAN RAMON, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced it will release first quarter 2022 financial results on Thursday, March 3, 2022, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.

CooperCompanies Announces Release Date for First Quarter 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $COO #ai--BOSS, the data technology powerhouse made up of PhDs and data scientists names Jim Russo as Chief Operating Officer. With a proven history in business leadership and organization, Russo is set to intentionally streamline daily procedures, as well as provide strategic planning and support as the leadership grows capital and brings the software product to market in 2022. Russo joins BOSS with more than three decades of experience in business leadership roles. Ca

BOSS Names Jim Russo COO

Henry Schein

HSIC vs. COO: Which Stock Is the Better Value Option?

HSIC vs. COO: Which Stock Should Value Investors Buy Now?

SAN RAMON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced it has completed the previously announced definitive purchase agreement to acquire Generate Life Sciences, a leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage (cord blood & cord tissue), for a purchase price of approximately $1.6 billion.

CooperCompanies Completes Acquisition of Generate Life Sciences®

Cooper Companies Inc (NYSE: COO) reported that Q4 sales increased 11% Y/Y to $759.1 million, beating the consensus of $747.85 million. Q4 adjusted EPS of $3.28 increased 4% Y/Y, missing the consensus of $3.37.

Cooper Companies Reports Mixed Q4 Results

Cooper Companies' (COO) fiscal fourth-quarter results reflect solid segmental and geographical performances.

Cooper Companies (COO) Q4 Earnings Lag Estimates, Margins Up

The Cooper Companies (COO) delivered earnings and revenue surprises of -2.67% and 1.52%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

The Cooper Companies (COO) Q4 Earnings Lag Estimates

﻿SAN RAMON, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced financial results for its fiscal fourth quarter and full year ended October 31, 2021.

CooperCompanies Announces Fourth Quarter and Full Year 2021 Results

Cooper Companies (NYSE:COO) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement.

Earnings Outlook For Cooper Companies

The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Cooper Companies (COO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Dan McBride to Take on Expanded Responsibilities as EVP, Chief Operating Officer

CooperCompanies Announces Executive Management Changes

Cooper Companies has long been a steady play on soft contact lenses and owns a women's surgical business as well. After displaying strong operating momentum, management is growing the non-lens business through a sizeable M&A deal, something which concerns investors.

Cooper Companies: Looking Through A Lens

Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.

Cooper Companies' (COO) Buyout to Boost Women's Healthcare

LOS ANGELES, Nov. 10, 2021 /PRNewswire/ -- Generate Life Sciences® announces it has entered into an agreement to be acquired by the publicly held healthcare company, CooperCompanies (NYSE: COO) and become part of CooperSurgical, a recognized global leader in women's health and fertility solutions. For over 40 years Generate has been helping to grow and protect healthy families by providing reproductive, newborn stem cell (umbilical cord blood and tissue) and related genetic services.

Generate Life Sciences to be acquired by CooperCompanies

SAN FRANCISCO, Nov. 10, 2021 /PRNewswire/ -- GI Partners, a leading private investment firm, today announced the signing of a definitive agreement to sell Generate Life Sciences ("Generate"), a leading life sciences platform that provides reproductive and newborn stem cell (umbilical cord blood and tissue) services, to CooperCompanies (NYSE:COO). Generate Life Sciences was created by GI Partners in 2018 as the combination of California Cryobank Life Sciences, an industry-leading donor sperm and egg bank, and Cord Blood Registry, a leading provider of newborn stem cell services.

News for Cooper Companies Stock (COO)